And using STINGa in Herceptin-resistant HER2+ BC could reverse IFN signaling activity, which promotes anti-tumor immune response and have a synergistic anti-tumor effect with DS-8201 in vitro and in vivo. This evidence concerns the gene IFNA1 and neoplasm.